These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 9950596

  • 1. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model.
    Romanowski EG, Bartels SP, Gordon YJ.
    Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):378-84. PubMed ID: 9950596
    [Abstract] [Full Text] [Related]

  • 2. HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model.
    Gordon YJ, Romanowski EG, Araullo-Cruz T.
    Cornea; 1994 Nov; 13(6):516-20. PubMed ID: 7842711
    [Abstract] [Full Text] [Related]

  • 3. Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis.
    Kaufman HE, Varnell ED, Thompson HW.
    Arch Ophthalmol; 1998 Jun; 116(6):777-80. PubMed ID: 9639447
    [Abstract] [Full Text] [Related]

  • 4. Cidofovir and experimental herpetic stromal disease.
    Kaufman HE, Varnell ED, Thompson HW.
    Arch Ophthalmol; 1999 Jul; 117(7):925-8. PubMed ID: 10408458
    [Abstract] [Full Text] [Related]

  • 5. Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model.
    Romanowski EG, Gordon YJ.
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):158-62. PubMed ID: 11133861
    [Abstract] [Full Text] [Related]

  • 6. Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model.
    Romanowski EG, Araullo-Cruz T, Gordon YJ.
    Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):253-7. PubMed ID: 9019458
    [Abstract] [Full Text] [Related]

  • 7. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model.
    Romanowski EG, Yates KA, Teuchner B, Nagl M, Irschick EU, Gordon YJ.
    Invest Ophthalmol Vis Sci; 2006 May; 47(5):2021-6. PubMed ID: 16639011
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model.
    Romanowski EG, Gordon YJ.
    Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):460-3. PubMed ID: 10670476
    [Abstract] [Full Text] [Related]

  • 9. Trifluridine decreases ocular HSV-1 recovery, but not herpetic lesions after timolol iontophoresis.
    Rootman DS, Hill JM, Haruta Y, Reidy JJ, Kaufman HE.
    Invest Ophthalmol Vis Sci; 1989 Apr; 30(4):678-83. PubMed ID: 2539342
    [Abstract] [Full Text] [Related]

  • 10. Management of acyclovir-resistant herpes simplex virus.
    Chilukuri S, Rosen T.
    Dermatol Clin; 2003 Apr; 21(2):311-20. PubMed ID: 12757254
    [Abstract] [Full Text] [Related]

  • 11. (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis.
    Maudgal PC, De Clercq E.
    Invest Ophthalmol Vis Sci; 1991 May; 32(6):1816-20. PubMed ID: 1851733
    [Abstract] [Full Text] [Related]

  • 12. Effect of oral valaciclovir on herpetic keratitis.
    Higaki S, Itahashi M, Deai T, Fukuda M, Shimomura Y.
    Cornea; 2006 Dec; 25(10 Suppl 1):S64-7. PubMed ID: 17001196
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the antiherpetic activity of acyclovir in rabbits.
    Trousdale MD, Nesburn AB.
    Am J Med; 1982 Jul 20; 73(1A):155-60. PubMed ID: 6285707
    [Abstract] [Full Text] [Related]

  • 14. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model.
    Romanowski EG, Gordon YJ, Araullo-Cruz T, Yates KA, Kinchington PR.
    Invest Ophthalmol Vis Sci; 2001 Jul 20; 42(8):1812-5. PubMed ID: 11431446
    [Abstract] [Full Text] [Related]

  • 15. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model.
    Anand BS, Hill JM, Dey S, Maruyama K, Bhattacharjee PS, Myles ME, Nashed YE, Mitra AK.
    Invest Ophthalmol Vis Sci; 2003 Jun 20; 44(6):2529-34. PubMed ID: 12766053
    [Abstract] [Full Text] [Related]

  • 16. Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates.
    Yao YF, Inoue Y, Kase T, Uchihori Y, Mori Y, Ohashi Y.
    Graefes Arch Clin Exp Ophthalmol; 1996 Aug 20; 234 Suppl 1():S126-32. PubMed ID: 8871163
    [Abstract] [Full Text] [Related]

  • 17. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice.
    Afouna MI, Fincher TK, Zaghloul AA, Reddy IK.
    Int J Pharm; 2003 Mar 06; 253(1-2):159-68. PubMed ID: 12593946
    [Abstract] [Full Text] [Related]

  • 18. Effect of topical acyclovir therapy on experimental herpes simplex keratouveitis.
    Maudgal PC, Vrijghem JC, Molemans M, Missotten L.
    Arch Ophthalmol; 1985 Sep 06; 103(9):1389-92. PubMed ID: 3929753
    [Abstract] [Full Text] [Related]

  • 19. The treatment of herpes simplex virus epithelial keratitis.
    Wilhelmus KR.
    Trans Am Ophthalmol Soc; 2000 Sep 06; 98():505-32. PubMed ID: 11190039
    [Abstract] [Full Text] [Related]

  • 20. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice.
    Afouna MI, Mehta SC, Ghanem AH, Higuchi WI, Kern ER, DeClercq E, El-Shattawy HH.
    J Pharm Sci; 1999 May 06; 88(5):530-4. PubMed ID: 10229644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.